In this phase II study, the overall response rate (ORR) and safety of rituximab and bortezomib was evaluated in patients with relapsed or refractory follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with MCL (n = 25) and 11 patients with FL were enrolled. The ORR in patients with FL was 55% and 29% in patients with MCL. Adverse events (AEs) were reported by 13 patients with the most common ones being sensory neuropathy, fatigue, neutropenia, neuropathy and constipation. No serious AEs were reported.
Read more here.